RGNX - REGENXBIO Inc Market Capitalization-to-Revenue Ratio

Symbol and logo of brand REGENXBIO Corp (RGNX)

REGENXBIO Inc. (RGNX) is minimally susceptible to market volatility, as its success depends on patents and clinical trials. The historical P/S ratio illustrates the valuation trend, where the value 3.30 expresses the state of the metric. Growth is driven by NAV-vector licenses that generate royalties. Supply reliability is guaranteed by liquid nitrogen transportation, which is critical for preserving the properties of biomaterials.

REGENXBIO Inc (RGNX): Price-to-Revenue Ratio from 07/04/2022 to 11/15/2026

regenxbio.com (RGNX) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price Regenxbio|RGNX - Consensus Target
- market capitalization statistics:
Market Value REGENXBIO Corp|RGNX - Enterprise Value
- book capitalization indicators:
Net Assets per Share REGENXBIO|RGNX - Company Book Value|Capitalization to Book Value Ratio regenxbio.com|RGNX - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio REGENXBIO Inc.|RGNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient regenxbio.com|RGNX - Company Debts|Debt to Net Assets Ratio REGENXBIO Corp|RGNX - Company Long-Term Debts|Short-Term Indebtedness REGENXBIO|Immediate Liquidity Ratio regenxbio.com
- net income and valuation ratios data:
RGNX - Net Income|Net Profit Forecast REGENXBIO Inc.|RGNX - P/E Multiple|Price to Future Earnings Ratio REGENXBIO Corp|RGNX - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation REGENXBIO Corp|RGNX - Operating profit EBITDA|Net earnings per share (EPS TTM) REGENXBIO|RGNX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months regenxbio.com|RGNX - Earnings growth in current year|Expected net earnings per share growth next year REGENXBIO Inc.
- total revenue and sales volume data:
RGNX - Revenue and Sales Volume|Company Sales Forecast REGENXBIO|RGNX - P/S Multiple|Market Cap to Future Revenue Ratio REGENXBIO|RGNX - Sales Growth YoY (Last Twelve Months)
Fundamental company analysis:REGENXBIO, RGNX
Original product of REGENXBIO Inc.

Investors assess the resilience of REGENXBIO Inc. (RGNX) through the price-to-sales ratio, which is critical for a business generating stable royalties from the licensing of the Inertia platform. By analyzing the company's P/S ratio, you determine the extent of the premium paid for future cash flows from patents, where extreme values on the chart signal either inflated market expectations or stagnating operational efficiency.

Competing companies

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio